Tango Therapeutics Announces First Patient Dosed in Phase I/II Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD= Cancers

Tango Therapeutics, Inc. announced that the first patient has been dosed in the Phase I/II trial evaluating TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers. TNG348 is a novel, selective inhibitor of USP1.